

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

NCT07209371

Status	RECRUITING
Phase	Phase 2
Sponsor	Fred Hutchinson Cancer Center
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (7)

- Age e 18 years
- Ability to understand and willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of potential study participants
- Clinical diagnosis of IgA monoclonal gammopathy of undetermined significance (MGUS) based on International Myeloma Working Group (IMWG)-2014 criteria (Rajkumar et al, Lancet Oncology, 2014)
- Agree to use adequate contraception
- For women of child-bearing potential: prior to study entry and for the duration of study participation
- ... and 2 more (see full listing online)

Exclusion (3)

- Participants who are receiving other investigational agents
- Pregnant women
- Known hypersensitivity to rifaximin

Locations (1 total)

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States